Quest Diagnostics delivered a robust first quarter with over 9% organic revenue growth and a 13% increase in adjusted EPS, driven by broad-based demand and operational efficiencies.

• Organic revenue growth nearly entirely fueled by clinical innovations, new clinical areas like dialysis testing, and strategic collaborations.
• Double-digit revenue growth in hospital channels, especially through lab solutions with Corewell Health, complemented by expanding partnerships and new lab openings.
• Consumer health revenue surged, supported by strong repeat customer engagement and expanding lab insights integrated into digital health platforms.
• Continued leadership in diagnostics for Alzheimer's and cardiometabolic markers, reflecting successful innovation such as the AD-Detect blood test and new biomarker guidelines.
• Management raises full-year revenue and EPS guidance, reflecting confidence in sustained momentum and strategic execution.